Venus Remedies Ltd.
Fundamentals
- Market cap
- ₹2,603 cr
- P/E
- 25.32×
- ROE
- 8.08%
- Debt / equity
- 0.00
- Div yield
- 0.54%
- 52-week range
- 416.00 — 1943.80
Venus Remedies Ltd.
Latest quarter · Jun 2026
Strength & growth
The timeline — 6 notes on Venus Remedies Ltd.
July 2026
- 20 Jul 26 · 6:43 PM IST Brief Brief · Earnings · Small cap
Venus Remedies Q1 net profit more than doubles to ₹25.53 cr
Standalone revenue rose 30% to ₹178.80 cr from ₹137.13 cr a year ago. EBITDA jumped to ₹39.11 cr. Board approved technical MoA alteration.
- 20 Jul 26 · 6:37 PM IST Brief Brief · Earnings · Small cap
Venus Remedies Q1 profit more than doubles on 30% revenue jump
Revenue rose to ₹178.80 crore and net profit hit ₹25.53 crore from ₹11.70 crore a year ago. Company remains debt-free.
May 2026
- 26 May 26 · 10:10 PM IST Brief Brief · Earnings · Small cap
Venus Remedies reports audited results and declares dividend
The company confirmed its previously disclosed annual figures and recommended a final dividend of ₹10 per share.
- 26 May 26 · 10:07 PM IST Brief Brief · Earnings · Small cap
Venus Remedies posts 89% profit jump and names new board members
The company reported a standalone net profit of ₹99.3 crore for FY26. It also appointed Saransh Chaudhary as a whole-time director.
- 26 May 26 · 9:54 PM IST Brief Brief · Earnings · Small cap
Venus Remedies profit jumps 89% as annual revenue hits ₹768.7 cr
The company reported a standalone net profit of ₹99.3 crore for FY26, up from ₹52.6 crore, and proposed a final dividend of ₹10 per share.
- 22 May 26 · 11:56 AM IST Lead Lead · Regulatory · Small cap
Venus Remedies gets first global approval for oncology drug in Saudi Arabia
The Saudi FDA's nod for Plerixafor lets Venus move from commodity drugs into higher-value oncology. Saudi Arabia is the largest Gulf pharma market.